SPONSORSHIP ALLIANCE NEWS
Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer (NSCLC).
Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
This study develops AdaptSeg, a scalable framework leveraging cross-fraction anatomical priors to substantially improve OAR segmentation without per-patient retraining.
The purpose of this work was to develop and evaluate SAGE, a locally deployed LLM agent for autonomous VMAT optimization-priority tuning.
Neosoma is pleased to introduce the radiosurgery community to its AI-powered automated disease identification, volumetric measurement and lesion tracking software for neuro-oncology. Neosoma’s Zero-Click solution analyzes MR images within seconds, providing target volume contours for treatment planning, changes over multiple timepoints and relevant statistics. These results are presented conveniently in interactive dashboards improving a clinician’s understanding of the patient.
Additionally, two Category 3 CPT Codes are applicable to Neosoma’s solution for potential reimbursement.
Please use the link below to schedule a 20-minute software demonstration; we are also happy to schedule time at the ASTRO Scientific Meeting later this month.
Radiosurgery (stereotactic body radiation therapy, SBRT) is considered a standard option in the treatment of spinal metastases.
You know the dilemma: effective pain relief and high tumor control are achievable today—yet the question remains of how to protect the spinal cord without compromise.
Decline of quality of life (QOL) and cognitive function is common for brain metastases patients receiving radiotherapy but there is currently no standard of care for addressing those symptoms. This phase 2 randomized controlled trial examined the efficacy of early neuropsychological evaluation and integration to preserve QOL and cognition for patients treated with radiation for brain metastases.
Background:
Radiation necrosis (RN) is a recognized complication of stereotactic radiosurgery (SRS) for brain metastases, typically occurring within 6–24 months after treatment. Late RN occurring several years after SRS remains uncommon and may present substantial diagnostic challenges, particularly in patients with prolonged systemic immune exposure and evolving imaging abnormalities.
Advances in local and systemic therapy are continuously improving overall survival in cancer patients – yet at the same time, they are driving an increase in spinal metastases.
Milestone underscores growing clinical adoption of vault-free, cobalt-free stereotactic radiosurgery for advanced, patient-centered brain tumor treatment
We are pleased to invite submissions to our Special Issue in Cancers focused on innovative advances in neuro-oncology imaging and radiotherapy. Topics of interest include advanced MRI, amino acid PET, DOTATATE imaging, radiomics, AI applications, SRS/SBRT, proton therapy, FLASH radiotherapy, BNCT, re-irradiation, connectomics-guided radiotherapy, and other personalized treatment approaches for primary and metastatic CNS tumors. Original research, reviews, technical reports, and multidisciplinary perspectives are welcome.
Manuscript submission deadline: March 31, 2027
FLASH therapy is defined by ultra-rapid radiation delivery in a fraction of a second. Originally conceived to enhance precision by completing treatment before a patient's natural bodily movements occurred, the research has shifted following a major biological discovery.
Multicenter analysis: Radiosurgery proves to be an effective and safe option for pediatric lesions of the central nervous system (CNS)
Primary brain tumors account for approximately 20 to 27% of all tumors in children, making them the most common solid tumors in this patient group. [1-4]
Surgery, conventional radiation therapy, and systemic therapies are considered standard in pediatric neurooncology.
New findings from a multicenter registry show that stereotactic radiosurgery (SRS) with the CyberKnife treatment system is an important and effective option for pediatric CNS lesions, particularly when conventional treatments are limited. [5]
The Stanford Department of Neurosurgery is now accepting applications for the 2026-2027 Clinical Fellowship in Neurosurgical Oncology and Stereotactic Radiosurgery. Under the direction of Dr. Steven D. Chang, this one-year GME program offers specialized training in CyberKnife treatment planning and delivery for a diverse range of oncologic and functional conditions.
Interested applicants who have completed an ACGME-accredited residency within the U.S or have 24 of months of Board-approved postgraduate training should email their CV, personal statement, and three letters of recommendation to Dr. David J. Park at djpark@stanford.edu